Royalty Pharma (RPRX) CFO linked entities sell 34,791 shares under 10b5-1 plan

Rhea-AI Filing Summary

Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.

Insider Trade Summary

Net Seller: 34,791 shares ($1,627,534)

Net Sell 8 txns

Insider Coyne Terrance P.

Role EVP & CFO

Sold 34,791 shs ($1.63M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	22,487	$46.6717	$1.05M
Sale	Class A Ordinary Shares	10,429	$47.0145	$490K
Sale	Class A Ordinary Shares	1,292	$46.6747	$60K
Sale	Class A Ordinary Shares	583	$47.0143	$27K
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 109,177 shares (Indirect, By TPC RP 2021, LLC); Class A Ordinary Shares — 1,500 shares (Direct)

Footnotes (1)

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	03/02/2026		S(1)		22,487	D	$46.6717(2)	109,177	I	By TPC RP 2021, LLC
Class A Ordinary Shares	03/02/2026		S(1)		10,429	D	$47.0145(3)	98,748	I	By TPC RP 2021, LLC
Class A Ordinary Shares	03/02/2026		S(1)		1,292	D	$46.6747(2)	46,344	I	TPC RP EPA1 LLC
Class A Ordinary Shares	03/02/2026		S(1)		583	D	$47.0143(3)	45,761	I	TPC RP EPA1 LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Royalty Pharma (RPRX) disclose for Terrance P. Coyne?

Royalty Pharma disclosed that EVP and CFO Terrance P. Coyne reported indirect open-market sales of 34,791 Class A ordinary shares on March 2, 2026. The trades were executed through affiliated entities TPC RP 2021, LLC and TPC RP EPA1 LLC, not in his personal name.

How many Royalty Pharma (RPRX) shares were sold and at what prices?

A total of 34,791 Class A ordinary shares were sold in open-market transactions. Weighted average prices reported were $46.6717, $47.0145, $46.6747, and $47.0143 per share, with underlying trades occurring within specified ranges around those averages on March 2, 2026.

Were the Royalty Pharma (RPRX) insider sales by Terrance P. Coyne pre-planned?

Yes. All reported transactions were effected under a Rule 10b5-1 trading plan adopted by Terrance P. Coyne on August 8, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio management from opportunistic trading concerns.

How are the sold Royalty Pharma (RPRX) shares held in relation to Terrance P. Coyne?

The Form 4 shows the sold Class A ordinary shares were held indirectly through TPC RP 2021, LLC and TPC RP EPA1 LLC. Additional indirect holdings are reported through IRAs and a spouse’s accounts, plus a direct position, all reflecting different ownership channels tied to Coyne.

What price ranges applied to the Royalty Pharma (RPRX) insider sales?

Footnotes explain that some sales occurred in multiple trades at prices ranging from $45.93 to $46.92 per share, and others between $46.94 and $47.16 per share. Reported prices are weighted averages, and detailed breakdowns are available upon written request to relevant parties.

What ongoing Royalty Pharma (RPRX) holdings are reported after these transactions?

Post-transaction figures show continuing indirect positions, including 98,748 and 45,761 Class A ordinary shares held via TPC RP 2021, LLC and TPC RP EPA1 LLC, plus additional indirect holdings through IRAs and a spouse, and a direct holding of 1,500 shares as of March 2, 2026.